Image Content Enhancement Through Salient Regions Segmentation for People With Color Vision Deficiencies.

Color vision deficiencies affect visual perception of colors and, more generally, color images. Several sciences such as genetics, biology, medicine, and computer vision are involved in studying and analyzing vision deficiencies. As we know from visual saliency findings, human visual system tends to fix some specific points and regions of the image in the first seconds of observation summing up the most important and meaningful parts of the scene. In this article, we provide some studies about human visual system behavior differences between normal and color vision-deficient visual systems. We eye-tracked the human fixations in first 3 seconds of observation of color images to build real fixation point maps. One of our contributions is to detect the main differences between the aforementioned human visual systems related to color vision deficiencies by analyzing real fixation maps among people with and without color vision deficiencies. Another contribution is to provide a method to enhance color regions of the image by using a detailed color mapping of the segmented salient regions of the given image. The segmentation is performed by using the difference between the original input image and the corresponding color blind altered image. A second eye-tracking of color blind people with the images enhanced by using recoloring of segmented salient regions reveals that the real fixation points are then more coherent (up to 10%) with the normal visual system. The eye-tracking data collected during our experiments are in a publicly available dataset called Eye-Tracking of Color Vision Deficiencies

A feature based approach for loaded/unloaded drones classification exploiting micro-doppler signatures

This paper deals with the problem of loaded/unloaded drones classification. Precisely, exploiting the different micro-Doppler signatures exhibited by a drone with both any load and payloads of different weights, a novel signature extraction procedure is developed for automatic recognition purposes. The developed algorithms is based on a novel adaptation of the spectral kurtosis technique to the problem at hand, specifically the analysis of narrowband and wideband spectrograms of the radar echoes reflected by the drones. In addition, the principal component analysis is used to reduce the feature vector size. The experiments conducted on measured bistatic radar data prove the effectiveness of the proposed method in separating the quoted classes of object

Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation

Background and Objectives: Psoriasis (PsO) and psoriatic arthritis (PsA) are often undertreated and require a multidisciplinary approach. In recent years, patent expiration has allowed the introduction of tumor necrosis factor inhibitor (antiTNF) biosimilars, which have stimulated a significant increase in the use of biological therapies. This article reports the f indings of a multidisciplinary approach to achieve a consensus on the use of adalimumab in patients with PsO or PsA. Methods: A voting panel of 36 Italian dermatologists and rheumatologists were chosen by eight Italian clinicians (the Board), to provide a consensus on the real-world management of PsO and PsA with adalimumab using the Delphi Method, comprising three survey rounds. Twelve statements were defined by the Board and submitted to the panel (rating scale 1–7). Results: Clinicians reached a wide consensus on the effectiveness (score 6–7: 67%) and long-term efficacy (6–7: 100%) of adalimumab in all clinical forms of PsO and PsA, including pediatric patients (6–7: 85%). Considering cost-effectiveness and safety, adalimumab is suggested as a first-line treatment in patients with enthesitis, predominant peripheral arthritis, axial involvement or associated inflammatory bowel disease (IBD) or uveitis. Adalimumab can be also considered after failure of etanercept (6–7: 94%). Conclusion: Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure

Occipital atrophy signature in prodromal Lewy bodies disease

Introduction: Dementia with Lewy bodies (DLB) is typically characterized by parietal, temporal, and occipital atrophy, but less is known about the newly defined prodromal phases. The objective of this study was to evaluate structural brain alterations in prodromal DLB (p-DLB) as compared to healthy controls (HC) and full-blown dementia (DLB-DEM). Methods: The study included 42 DLB patients (n = 20 p-DLB; n = 22 DLB-DEM) and 27 HC with a standardized neurological assessment and 3-tesla magnetic resonance imaging. Voxel-wise analyses on gray-matter and cortical thickness were implemented to evaluate differences between p-DLB, DLB-DEM, and HC. Results: p-DLB and DLB-DEM exhibited reduced occipital and posterior parieto-temporal volume and thickness, extending from prodromal to dementia stages. Occipital atrophy was more sensitive than insular atrophy in differentiating p-DLB and HC. Occipital atrophy correlated to frontotemporal structural damage increasing from p-DLB to DLB-DEM. Discussion: Occipital and posterior-temporal structural alterations are an early signature of the DLB continuum and correlate with a long-distance pattern of atrophy

Induction of tissue plasminogen activator (tPA) by pituitary adenylate cyclase-activating polypeptide (PACAP) in Schwann cell-like cultures

Peripheral nerve regeneration is dependent on the ability of regenerating neurites to migrate through cellular debris and altered extracellular matrix at the injury site, grow along the residual distal nerve sheath conduit, and reinnervate synaptic targets. In cell culture, growth cones of regenerating axons secrete PACAP, a peptide known to induce the expression of the protease tPA1. Here we tested the hypothesis that PACAP might also stimulate peripheral glial cells to release tPA to participate in nerve regeneration. More specifically, we addressed whether PACAP promoted the release and expression of tPA in the Schwann cell-like culture RT4-D6P2T, which shares biochemical and physical properties with Schwann cells2. We found that PACAP dose- and time-dependently stimulated tPA expression. Maxadilan, a potent PACAP receptor agonist, mimicked the effect of PACAP, whereas VIP, a PACAP-related peptide, produced only a moderate response. PACAP ability to stimulate tPA expression seemed to be dependent on the Akt/CREB signaling cascade, as inhibition using the PI3K/Akt blocker wortmannin or the TrkA/B inhibitor K252a both significantly dampened PACAP-evoked tPA expression. A similar effect was obtained in cells treated with the PACAP/VIP receptor antagonist PACAP6-38. We conclude that PACAP through the Akt/CREB intracellular pathway, acts as a potent inducer of tPA expression and release in Schwann-cell like cultures

T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker

Simple Summary Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia. Given important therapeutic implications, it is crucial to identify T-LBL arising in this particular context. LIM domain only 2 (LMO2) is known to be overexpressed in almost all sporadic T-LBL and not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations. We retrospectively evaluated the clinical, morphological, immunohistochemical and molecular features of 11 cases of T-LBL occurring in the setting of myeloid/lymphoid neoplasms with eosinophilia and investigated the immunohistochemical expression of LMO2 in this setting of T-LBL. Interestingly, 9/11 cases were LMO2 negative, with only 2 cases showing partial expression. In our study, we would suggest that LMO2 immunostaining, as part of the diagnostic panel for T-LBL, may represent a useful marker to identify T-LBL developing in the context of myeloid/lymphoid neoplasms with eosinophilia. Background: Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine receptor. The correct identification of this category has relevant therapeutic implications. LIM domain only 2 (LMO2) is overexpressed in most T-LBL, but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP). Methods and Results: We retrospectively evaluated 11 cases of T-LBL occurring in the context of M/LNs-Eo. Clinical, histological, immunohistochemical and molecular features were collected and LMO2 immunohistochemical staining was performed. The critical re-evaluation of these cases confirmed the diagnosis of T-LBL with morphological, immunohistochemical and molecular features consistent with T-LBL occurring in M/LNs-Eo. Interestingly, LMO2 immunohistochemical analysis was negative in 9/11 cases, whereas only 2 cases revealed a partial LMO2 expression with a moderate and low degree of intensity, respectively. Conclusions: LMO2 may represent a potentially useful marker to identify T-LBL developing in the context of M/LNs-Eo. In this setting, T-LBL shows LMO2 immunohistochemical profile overlapping with cortical thymocytes and iT-LBP, possibly reflecting different molecular patterns involved in the pathogenesis of T-LBL arising in the setting of M/LNs-Eo

Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Objective. Our aim was to summarize and evaluate the current quality of evidence regarding the efficacy of therapies for cutaneous psoriasis (PsO) in patients with psoriatic arthritis (PsA).Methods. A literature search of MEDLINE, Embase, Cochrane Library databases, and conference abstracts was conducted to identify interventional randomized controlled trials in patients with PsA between February 2013 and December 2021. Studies were included if PsO outcomes included achieving at least 75% improvement in the Psoriasis Area and Severity Index and the blinded comparison period was >= 10 weeks. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was employed to assess quality of the evidence to inform and update the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations.Results. A total of 116 studies and 36 abstracts identified in the initial search were screened. A total of 37 studies (40 treatment arms) met the criteria for final inclusion. Phosphodiesterase 4 inhibitors, Janus kinase inhibitors, and tyrosine kinase 2 inhibitors, interleukin 17 inhibitors (IL-17i), IL-12/23i, IL-23i, and tumor necrosis factor inhibitors (TNFi) had high-quality data broadly supporting the efficacy of each class for plaque PsO over placebo. Head-to-head studies with high-quality data supported both IL-17i and IL-23i over TNFi.Conclusion. Several pharmacologic therapeutic classes have high-quality evidence demonstrating efficacy for cutaneous PsO in the PsA population. The findings will be integrated into the 2021 GRAPPA treatment recommendations, intended to guide selection of a therapeutic class where efficacy in 1 or more cutaneous or musculoskeletal domains is required

Incidentally discovered pheochromocytoma and aldosterone-producing adenoma in the same adrenal gland

Simultaneous occurrence of pheochromocytoma and aldosterone-producing adrenocortical tumor has been rarely reported in patients with symptoms or findings suggestive for both neoplasms. Herein, we report and discuss on a challenging case of synchronous pheochromocytoma and aldosterone-producing adenoma incidentally detected in the same adrenal gland and documented by biochemical studies and pathological examination